April 22 (Reuters) - Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition. (Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.22 USD | -2.99% | -7.05% | -15.77% |
18/06 | Abeona Therapeutics Files for $300 Million Mixed Shelf, $75 Million At-The-Market Offering | MT |
30/05 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.77% | 173M | |
+38.36% | 52.73B | |
+39.47% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- US FDA declines to approve Abeona's skin disorder treatment